EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real‐World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST‐CLL Study

Francesca Perutelli iD, Matteo Arata, Raffaella Pasquale, Sara Pepe iD, Maura Nicolosi, Marina Deodato, Ilaria Piras, Erika Fioribello, Alessandro Bosi, Riccardo Moia iD, Andrea Ferrario, Michela Schirru und 16 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70246 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2026. Verfasst von Francesca Perutelli und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, University of Torino & University Division of Hematology, A.O.U. Città della Salute e dell…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple targeted agents are available for first‐line treatment of chronic lymphocytic leukemia (CLL), yet the absence of mature head‐to‐head comparisons makes treatment selection challenging. The prospective, multicenter FIRST‐CLL study evaluated real‐world treatment allocation, and the contribution of biological, clinical, logistical and patient‐related factors to first‐line regimen choice in Italy. 285 consecutive patients with CLL/small lymphocytic lymphoma initiating first‐line therapy across 13 Centers were included. Treating physicians rated predefined variables guiding treatment selection using the 5‐point relevance score . Overall, 116 patients (41%) received continuous Bruton tyrosine kinase inhibitors (BTKi), 114 (40%) ibrutinib plus venetoclax (IV), and 55 (19%) venetoclax plus obinutuzumab (VO). Continuous BTKi were more frequently prescribed in older and comorbid patients, whereas IV was preferentially used in younger individuals. TP53 disruption was associated with BTKi use, while mutated immunoglobulin heavy chain status was common in patients receiving VO. According to relevance scores , age, treatment duration and administration route, and patient preference were the most influential determinants of treatment selection. Comorbidity burden additionally guided BTKi prescription, whereas molecular features were more relevant in the selection of fixed‐duration regimens. This study offers a real‐world quantitative assessment of treatment decision drivers in frontline CLL, offering a data‐driven framework to interpret clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedMaleMiddle AgedAged, 80 and overProspective StudiesAdeninePiperidinesBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntibodies, Monoclonal, HumanizedProtein Kinase Inhibitors

Substanzen

ibrutinibAdeninePiperidinesBridged Bicyclo Compounds, HeterocyclicvenetoclaxobinutuzumabSulfonamidesAntibodies, Monoclonal, HumanizedProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Molecular Biotechnology and Health Sciences, University of Torino & University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
  • SOC Clinica Ematologica-Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
  • Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Roma, Italy.
  • Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
  • Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
  • Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS G. Brotzu, Cagliari, Italy.

ORCID-Profile: Francesca Perutelli, Sara Pepe, Riccardo Moia, Elia Boccellato, Martina Bullo, Andrea Galitzia, Marta Coscia, Gianluca Gaidano, Michele Merli, Roberta Murru, Anna Maria Frustaci, Jacopo Olivieri, Francesca Romana Mauro, Candida Vitale

Zitieren

APA

Perutelli, F., Arata, M., Pasquale, R., Pepe, S., Nicolosi, M., Deodato, M., Piras, I., Fioribello, E., Bosi, A., Moia, R., Ferrario, A., Schirru, M., Boccellato, E., Bullo, M., Gottardi, D., Foglietta, M., Galitzia, A., Coscia, M., Gaidano, G., …, & Vitale, C. (2026). Real‐World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST‐CLL Study. Hematological Oncology. https://doi.org/10.1002/hon.70246

Vancouver

Perutelli F, Arata M, Pasquale R, Pepe S, Nicolosi M, Deodato M, et al. Real‐World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST‐CLL Study. Hematological Oncology. 2026. doi:10.1002/hon.70246

BibTeX
@article{Perutelli2026,
  author = {Perutelli, Francesca and Arata, Matteo and Pasquale, Raffaella and Pepe, Sara and Nicolosi, Maura and Deodato, Marina and Piras, Ilaria and Fioribello, Erika and Bosi, Alessandro and Moia, Riccardo and Ferrario, Andrea and Schirru, Michela and Boccellato, Elia and Bullo, Martina and Gottardi, Daniela and Foglietta, Myriam and Galitzia, Andrea and Coscia, Marta and Gaidano, Gianluca and Merli, Michele and Salvetti, Chiara and Murru, Roberta and Frustaci, Anna Maria and Freilone, Roberto and Olivieri, Jacopo and Mauro, Francesca Romana and Bruno, Benedetto and Vitale, Candida},
  title = {Real‐World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST‐CLL Study},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70246}
}
Kostenlos starten →